Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Lung cancEr fusiOn geNes: a new dIagnostic Device (LEONID)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: SME instrument
Countries involved: Italy,Italy
Call: Clinical research for the validation of biomarkers and/or diagnostic medical devices (H2020-SMEINST-2-2014, 2014)
Start date: 2015-07-01
End date: 2016-12-31
Duration (months): 18.0
Total project cost (EUR): 1704000.0
EU funding (EUR): 1704000.0
Participants: 3
Project status: CLOSED

The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment. The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK. The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility. The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers. For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company’s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests’ results and can provide its new software through Diatech PGx or directly.

Keywords: lung cancer,nsclc,gene fusion,gene rearrangement,target therapy,personalized medicine,clinical validation,ros1,crizotinib,cabozantinib,tkis,ce ivd
CeLac and European consortium for a personalized medicine approach to Gastric Cancer (LEGACy)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Argentina,Spain,Spain,Belgium,Netherlands,Chile,Paraguay,Portugal,Mexico
Call: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC) (H2020-SC1-2018-Single-Stage-RTD, 2018)
Start date: 2019-01-01
End date: 2023-06-30
Duration (months): 54.0
Total project cost (EUR): 3993056.25
EU funding (EUR): 3577431.25
Participants: 11
Project status: SIGNED

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Keywords: gastric cancer,omics integrative epidemiology,personalised medicine
A unique multi-layer deposition process for optimised production of the next generation of Li-ion batteries. (Coldab)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Finland
Call: SME instrument (H2020-EIC-SMEInst-2018-2020-3, 2020)
Start date: 2020-10-01
End date: 2023-12-31
Duration (months): 39.0
Total project cost (EUR): 3470500.0
EU funding (EUR): 2301250.0
Participants: 1
Project status: SIGNED

Despite being an ideal solution to the global challenge of tackling the effects of transport emissions, Electric Vehicles (EVs) have not yet achieved significant mass market penetration. This is mostly due to the fact that the development in the EV battery industry has been rather incremental, without revolutionary breakthrough since 1991. LiBs represent the gold standard in the industry; however, they suffer from many issues which are detrimental to the widespread adoption of EVs. These are mainly related to insufficient performance, in terms of size, energy density and safety, expensive and rigid production while existing deposition methods has low production rate thus affecting the overall supply of EVs in comparison to high-growth demand (CAGR of 20%). Pulsedeon developed Coldab, a coating technology leveraging Ultra-Short Pulsed Laser Deposition (USPLD), that can optimize production of LiB & its components on a large scale. Coldab’s unique USPLD process allows cost-effective manufacturing of a new class of safer, smart tailored, high-performance EV batteries. Pulsedeon favours the competitiveness of European battery manufacturers by offering a cutting-edge manufacturing process and promotes a clean environment. To increase the EV’s affordability & improve their performance, Coldab brings battery manufacturing to a new level of scalability, at the same time preserving performance by increasing the battery’s energy density and safety. Overall objective of Pulsedeon is to introduce a paradigm shifting within EV battery manufacturing process to facilitate the widespread adoption of EVs. During the innovation project, Pulsedeon intends to upgrade & validate Coldab system to automate the production of LiBs & its components, conduct extensive validation tests of the system and produced LiBs, setup a scalable supply chain & finally conduct pilot tests with 8 battery OEMs confirming technology’s performance and advantages in a commercial environment.

Keywords: battery manufacturing,electric vehicles,coating,lithium ion battery,ultra short pulsed laser,deposition,ev batteries,multi layer fabrication,uspld deposition,next generation of lithium ion
Using a protein approach with Waddlia chondrophila and zebrafish as model organisms to conquer the female tubal factor subfertility market (PROZE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: United Kingdom
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-01
End date: 2018-08-31
Duration (months): 12.0
Total project cost (EUR): 111687.5
EU funding (EUR): 111687.5
Participants: 1
Project status: CLOSED

TubaScan Ltd. is a Dutch R&D-performing SME developing molecular diagnostic assays based on human biomarkers with a strong focus on the subfertility market. We predict female subfertility as a result of infection with the bacterium Chlamydia trachomatis. However, to be able to conquer the female subfertility market TubaScan is in need of a competitive edge. Currently, innovation within the company and exploration of new markets is hampered by a lack of specific tools and models. PROZE will enable TubaScan to solidify our position as an innovative biotech SME, bring a novel assay to the subfertility market and establishing R&D programmes for new markets. PROZE will do this through hiring an Innovation Associate (IA). • The IA will complete the available biomarker panel with protein. • The IA will provide a model organism to study Chlamydia-like pathogenesis (i.e. Waddlia chondrophila). • The IA will develop a unique in vivo model to study host mechanisms involved in Chlamydia-like pathogenesis (i.e. Waddlia chondrophila zebrafish embryo infection model, with CRISPR/Cas approaches for functional analysis). • The IA will perform a technical feasibility study for and investigate the market potential of the WaddliaSCAN, an assay predicting female subfertility based on measuring the host immune response to Waddlia chondrophila proteins. PROZE will not only bring major benefits for TubaScan, but is focused around the training of the Innovation Associate, thereby creatly improving his/her career development. • Gaining novel technical skills and building an own research line with translational diagnostic applications. • Gaining innovation and business management skills in a multidisciplinary setting. • A training programme tailored to his/her specific needs and major contribution to personal career development.

Keywords: protein biomarkers,diagnostics,protein functionality,tubal pathology,female subfertility,zebrafish infection model,training
Nanoscale Stress Imaging with Imperfect Diamonds (Stress Imaging)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Biotechnology and Biosystems Engineering
Panel description: Biotechnology using all organisms, biotechnology for environment and food applications, applied plant and animal sciences, bioengineering and synthetic biology, biomass and biofuels, biohazards
Countries involved: Netherlands
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-03-01
End date: 2023-08-31
Duration (months): 78.0
Total project cost (EUR): 1454713.75
EU funding (EUR): 1454713.75
Participants: 1
Project status: SIGNED

My goal is to optically detect the magnetic resonance of free radicals/ROS inside cells. Radicals are suspected to play a crucial role in numerous pathogenic conditions including diseases responsible for most deaths worldwide (as arteriosclerosis, cancer, immune responses to pathogens). They are also involved in many processes in healthy cells as mitochondrial metabolism or aging of cells and part of the working mechanism of many drugs. Despite their relevance relatively little is known about where and when radicals are built, how they work or which ones play a role. Their short lifetime and reactivity poses a problem for many state of the art methods. Thus they are often a bottleneck in understanding stress responses. My goal is to develop a method, which can detect their magnetic resonance in the nanoscale. The method is based on a fluorescent defect in diamond, which changes its optical properties based on its magnetic surrounding. While this technique has been able to detect even the faint signal of a single electron spin, this technique is entirely new to biological fields. We can localize where, when and how much of a certain radical is generated with nm resolution. This is impossible with the current state of the art. Furthermore, since we obtain spectra we can also differentiate radicals to some extent. I am proposing to investigate two systems: 1) the involvement of radicals in the aging of yeast cells 2) the response of macrophages to stress. In the first project I will test the so-called free radical theory, which states that organisms age because cells accumulate free radical damage over time. In the second project I will answer the question how a macrophage reacts to the impact of a pathogen or a drug. Outcomes of this project would enable us to increase our understanding on how stress responses work on a molecular level. This will open up new possibilities to assess if and how drugs are working or how and why certain pathogens are worse than others.

Keywords: imaging,free radicals,nv centers,diamond
The neural basis of visual interaction between scenes and objects (SEEING FROM CONTEXT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Italy
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2016-06-01
End date: 2018-05-31
Duration (months): 24.0
Total project cost (EUR): 180277.2
EU funding (EUR): 180277.2
Participants: 1
Project status: CLOSED

We easily categorize places and objects in a single glance, a computationally complex task presenting a central challenge for vision neuroscience. Considerable evidence points to a division of scene and object processing into two distinct neural pathways, relying on different types of visual cues. However, scenes and objects are also known to strongly interact in visual perception, as seen in contextual effects of background on object perception. At present, the neural mechanisms by which scenes and objects interact remain unknown, leaving a critical gap in our understanding of these two major visual paths. The main goal of this multi-method proposal is to uncover the neural mechanisms of scene-object interactions. I therefore propose three competing theoretical models. A parallel model predicts only stimulus-driven representations of scenes and objects in the visual cortex. In contrast, interactive models predict that representations of scenes and objects in the visual cortex are influenced by one-another. However, whereas a visual-interactive model suggests direct interaction, a feedback model suggests that the interaction is mediated by frontal regions. To test this, I propose a novel psychophysical paradigm of seeing objects from scene context and scenes from object context. Thereby, I will examine how scene and object processing are affected by one-another and identify the potential neural sources of these modulations using fMRI (objective 1). Thereafter, I will use MEG to decode the timeline of these neural processes (objective 2). Establishing a clear neurocognitive model for scene-object interaction would not only advance our understanding of the two central paths of the ventral visual stream, but also significantly contribute to the definition of vision as an interactive system rather than a set of specialized parallel modules. Shifting from localized visual modules to interactive visual processes will broaden my expertise as a cognitive neuroscientist.

Keywords: scene perception,object perception,visual streams,visual context,top down perception,fmri
Demonstration of the GRAVI3 technology – innovative gravity foundation for offshore wind (DEMOGRAVI3)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure, clean and efficient energy
Theme: Low-cost, low-carbon energy supply
Action type: Innovation actions
Countries involved: Spain,Germany,Ireland,Spain,Norway,United Kingdom,Portugal,Portugal,Portugal
Call: Demonstration of renewable electricity and heating/cooling technologies (H2020-LCE-2015-2, 2015)
Start date: 2016-01-01
End date: 2019-12-31
Duration (months): 48.0
Total project cost (EUR): 26523602.5
EU funding (EUR): 19037465.51
Participants: 15
Project status: CLOSED

Offshore wind business competitiveness is strongly related to substructures and offshore logistics. DEMOGRAVI3 addresses these areas through a very promising solution called GRAVI3. GRAVI3 is an innovative hybrid steel-concrete offshore sub-structure for transitional water depths between 35 and 60m. It will sustainably reduce the levelized cost of energy by up to 15% by combining the following vectors: - Using three concrete caissons, with water ballast, instead of more complex and costly steel solutions and anchoring systems - Using a smaller steel structure - Performing all construction and assembly onshore and towing the complete unit to the site where it is submerged with an innovative and robust method. - Preventing the use of heavy lift vessels and reducing the level of complexity and risk of offshore operations. GRAVI3 has undergone the typical technology development process and is presently at TRL5. The logical next steps is the demonstration at full scale in real operational conditions. Thus, the project fits perfectly to the addressed Call for Proposals as the project will support technology development and bring the technology close to market readiness. The proposed project will design, engineer, build, assemble, transport, install and demonstrate a full scale foundation, equipped with a 2 MW offshore wind turbine, in a consented and grid connected demonstration site. Additionally, the project will undertake further technology development for improved design and perform an in depth evaluation of the technology’s future industrialization, competitiveness and bankability. The core partners are committed to bring the GRAVI3 technology to market intending to 1) form a company with the objective to commercialize the GRAVI3 technology; 2) prepare themselves to take on important segments of the industrial value chain which will be put in place to move the GRAVI3 product forward; 3) foster the use of the technology, namely in the wind farms they are developing.

Keywords: offshore wind,gravity based foundation,self buoyant,reduced costs,lcoe,design and engineering,fabrication,demonstration,evaluation,technology roadmap,replication
Exploring the combined role of genetic and non-genetic factors for developing Age-Related Macular Degeneration: A systems level analysis of disease subgroups, risk factors, and pathways (EYE-RISK)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Understanding health, wellbeing and disease
Action type: Research and Innovation actions
Countries involved: Germany,Ireland,Spain,Spain,Germany,Germany,Switzerland,France,France,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom
Call: Understanding health, ageing and disease: determinants, risk factors and pathways (H2020-PHC-2014-two-stage, 2014)
Start date: 2015-05-01
End date: 2019-04-30
Duration (months): 48.0
Total project cost (EUR): 6069996.25
EU funding (EUR): 5972496.0
Participants: 15
Project status: CLOSED

Age-related macular degeneration (AMD) is the world’s most important age-related blinding disorder. The current proposal utilises epidemiological data describing clinical phenotype, molecular genetics, lifestyle, nutrition, and in-depth retinal imaging derived from existing longitudinal European epidemiological cohorts and biobanks to provide three major insights needed for long-lasting prevention and therapy for AMD: (a) the development of robust algorithms utilising genetic and non-genetic risk factors to identify personalised risks of developing advanced wet and dry AMD; (b) the identification of novel biomarkers for further stratification of disease risks. New insights from (a)+(b) will be used to elaborate preventive medical recommendations for highrisk subgroups of AMD patients; and (c) the identification of molecular drivers/biological pathways relevant for onset and progression of advanced AMD that will be used to identify and validate new therapeutic targets. Key deliverables are: 1. Determination of AMD frequency in Europe, and assessment of AMD risk for phenotypical, genetic, environmental, and biochemical risk factors and their interaction. (WP1-3) 2. Development of a web-based prediction model for personalised risk assessment of AMD based on integration of risk profiles derived from retinal imaging, molecular genetics, assessment of lifestyle, and biochemical testing. (WP4) 3. Modelling and functional characterisation of pathophysiological pathways identified from integrated analysis of current knowledge and the above risk profiles. (WP5) 4. Experimental testing and interpretation of pathophysiological consequences of risks at the molecular level. (WP6) 5. An extension and refinement of the prediction model (WP4) based on work in WP5 and WP6 to generate clinical guidelines for the medical management of high-risk subgroups of patients with AMD. (WP7) 6. Promotion and dissemination of newly gained knowledge towards AMD prevention and therapy development

Keywords: stratification,biomarkers,signalling,blindness,retina,degeneration
Development, Operation, and Quality Assurance of Trustworthy Smart IoT Systems (ENACT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Spain,Italy,Spain,Poland,Norway,Norway,Latvia,Latvia,France,France,France,United Kingdom
Call: R&I on IoT integration and platforms (H2020-IOT-2017, 2017)
Start date: 2018-01-01
End date: 2021-03-31
Duration (months): 39.0
Total project cost (EUR): 4928542.5
EU funding (EUR): 4928542.5
Participants: 18
Project status: CLOSED

To unleash the full potential of IoT, realizing the digital society and flourishing innovations in application domains such as eHealth, smart city, intelligent transport systems, and smart manufacturing, it is critical to facilitate the creation and operation of trustworthy Smart IoT Systems. Since smart IoT systems typically operate in a changing and often unpredictable environment, the ability of these systems to continuously evolve and adapt to their new environment is decisive to ensure and increase their trustworthiness, quality and user experience. The DevOps movement advocates a set of software engineering best practices and tools, to ensure Quality of Service whilst continuously evolving complex systems and foster agility, rapid innovation cycles, and ease of use . Therefore, DevOps has been widely adopted in the software industry . However, there is no complete DevOps support for trustworthy smart IoT systems today. The main technical goal of ENACT is to develop novel IoT platform enablers to: i) Enable DevOps in the realm of trustworthy smart IoT systems, and enrich it with novel concepts for end-to-end security and privacy, resilience and robustness strengthening trustworthiness, taking into account the challenges related to “collaborative” actuation and actuation conflicts. ii) Facilitate the smooth integration of these to leverage DevOps for existing and new IoT platforms and approaches (e.g., FIWARE, SOFIA, and TelluCloud). This will be accomplished by evolving current DevOps methods and techniques to support the agile development and operation of smart IoT systems, and provide a set of novel mechanisms to ensure quality assurance and trustworthiness, such as actuation conflict handling, continuous testing and delivery across IoT, edge and cloud spaces and end to end security and privacy management. Through this ENACT will provide a DevOps framework for smart IoT Systems

Keywords: devops,trustworthiness,sensing and actuation,software engineering